BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30713041)

  • 1. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
    Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
    Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
    Mazuelas H; Carrió M; Serra E
    Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling iPSC-derived human neurofibroma-like tumors in mice uncovers the heterogeneity of Schwann cells within plexiform neurofibromas.
    Mazuelas H; Magallón-Lorenz M; Fernández-Rodríguez J; Uriarte-Arrazola I; Richaud-Patin Y; Terribas E; Villanueva A; Castellanos E; Blanco I; Raya Á; Chojnacki J; Heyn H; Romagosa C; Lázaro C; Gel B; Carrió M; Serra E
    Cell Rep; 2022 Feb; 38(7):110385. PubMed ID: 35172160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
    Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
    Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
    Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
    Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
    Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
    Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
    Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
    J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
    Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
    Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline and somatic NF1 gene mutations in plexiform neurofibromas.
    Upadhyaya M; Spurlock G; Monem B; Thomas N; Friedrich RE; Kluwe L; Mautner V
    Hum Mutat; 2008 Aug; 29(8):E103-11. PubMed ID: 18484666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.
    Lévy P; Vidaud D; Leroy K; Laurendeau I; Wechsler J; Bolasco G; Parfait B; Wolkenstein P; Vidaud M; Bièche I
    Mol Cancer; 2004 Jul; 3():20. PubMed ID: 15255999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
    Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
    Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.
    Hummel TR; Jessen WJ; Miller SJ; Kluwe L; Mautner VF; Wallace MR; Lázaro C; Page GP; Worley PF; Aronow BJ; Schorry EK; Ratner N
    Clin Cancer Res; 2010 Oct; 16(20):5048-57. PubMed ID: 20739432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
    Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
    Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.